Pharmaids Pharmaceuticals share price & results
- Jun 2026
- Jun 2026
Bengaluru-based CRDMO-in-transition offering contract research, development and manufacturing services to pharma, biopharma, agro-chemical, medical-device and specialty-chemical customers in India and abroad.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 0.00 | −100.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | 2.1 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. | |
| Return on equity | -23.24 | −10.2 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | 39.63 | +180.4 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 18.52 | +14.6 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance −41.2% 1Y
1Y: ₹48.98 on 24 Oct 2025 → ₹28.78. High ₹52.38 (8 Dec 2025), low ₹26.9 (1 Jun 2026).
- Previous close
- ₹28.6
- Market cap
- ₹106 Cr
- 52-week range
- ₹26.9 – ₹52.38
- One year
- −43.25%
- Return on equity (TTM to Jun 2026)
- -23.24%
Overview
- Symbol
- NSE:PHARMAID
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Pharmaids Pharmaceuticals Ltd. does
Based on the company's own presentations, annual report and earnings calls.
Pharmaids Pharmaceuticals is a Bengaluru-headquartered public company, incorporated in 1989 and BSE-listed since 1994, that is repositioning itself into a Contract Research, Development and Manufacturing Organization (CRDMO). It aims to offer end-to-end research, development, manufacturing and allied services to customers in the pharma, biopharma, agro-chemicals, medical devices and specialty-chemicals industries, both in India and other countries. The Company operates through a group structure of subsidiaries rather than a single manufacturing site.
- Permanent employees
- 28
- Subsidiaries
- 4 (Anugraha Chemicals, Adita Bio Sys, Siri Labvivo Diet, Spring Labs)
- Land bank for proposed CRDMO facility
- 3.45 acres, Tumkur, Karnataka (held for proposed sale, not yet developed)
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 5 fiscal years held (Mar 2022 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +149% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1 | 1 | 0 | 1 | 6 | 1 | 3 | 0 |
| Expenses | 2 | 3 | 3 | 6 | 11 | 5 | 4 | 1 |
| Operating profit | -1 | -2 | -3 | -5 | -5 | -4 | -1 | -1 |
| Operating margin | −137.3% | −143.0% | −2069.2% | −435.7% | −76.7% | −442.2% | −40.1% | — |
| Other income | 0 | 0 | 1 | 0 | 3 | 0 | 0 | 4 |
| Interest | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -1 | -2 | -4 | -6 | -2 | -4 | -2 | 3 |
| Tax rate | −15.1% | −13.5% | −19.1% | −23.4% | −29.1% | −26.7% | −22.5% | 22.3% |
| Net profit | -1 | -2 | -3 | -4 | -2 | -3 | -1 | 2 |
| EPS (₹ per share) | -0.29 | -0.45 | -0.87 | -1.24 | -0.47 | -0.88 | -0.37 | 0.60 |
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 0 | 2 | 11 |
| Expenses | 7 | 10 | 25 |
| Operating profit | -7 | -7 | -14 |
| Other income | 1 | 1 | 4 |
| Interest | 0 | 2 | 3 |
| Depreciation | 0 | 0 | 0 |
| Profit before tax | -6 | -9 | -14 |
| Net profit | -5 | -7 | -10 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 10 | 21 | 35 | 35 | 35 | 35 |
| Reserves | -2 | 1 | 36 | 29 | 17 | 18 |
| Borrowings | 0 | 0 | 13 | 36 | 20 | 21 |
| Other liabilities | 2 | 2 | 1 | 15 | 26 | 10 |
| Total liabilities | 11 | 25 | 85 | 115 | 98 | 84 |
| Fixed assets | 0 | 0 | 17 | 24 | 55 | 8 |
| Capital work in progress | 0 | 2 | 2 | 4 | 3 | 5 |
| Investments | 0 | 3 | 53 | 53 | 0 | 53 |
| Other assets | 11 | 19 | 14 | 34 | 41 | 18 |
| Total assets | 11 | 25 | 85 | 115 | 98 | 84 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operations | -0 | -4 | -3 | -8 | -4 |
| Cash from investing | 0 | -5 | -73 | -19 | 25 |
| Cash from financing | 0 | 21 | 66 | 25 | -21 |
| Net cash flow | 0 | 12 | -10 | -2 | -0 |
| Free cash flow | -0 | -6 | -20 | -17 | 14 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 12 | 124 | — | 0 | 25 | 48 |
| Inventory days | 17 | 91 | 0 | 4198 | 1774 | 0 |
| Days payable | 22 | 236 | — | 0 | 2067 | — |
| Cash conversion cycle | 6 | -21 | — | 4198 | -267 | 48 |
| Working capital days | 3 | -18 | — | 14600 | -471 | -342 |
| Return on capital employed | 1.1% | 1.6% | −63.8% | −10.8% | −7.0% | −15.8% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Ownership
Who owns it
Public hold 67.02% as of Jun 2026.
- Promoters 32.99%
- Public 67.02%
Who is on the register
Named in the Jun 2026 filing
Every holder of Pharmaids Pharmaceuticals Ltd. above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| 28.52% | unchanged | |
| 14.53% | unchanged | |
| 7.99% | unchanged | |
| 7.72% | unchanged | |
| 4.45% | unchanged | |
| 4.32% | unchanged | |
| 2.21% | unchanged | |
| 2.03% | unchanged | |
| 1.24% | unchanged | |
| 0.02% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Pharmaids Pharmaceuticals Ltd.
Free account: one company. Everything above stays public.
Write why you follow Pharmaids Pharmaceuticals Ltd. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Pharmaids Pharmaceuticals Ltd.
Guides on how to read this kind of business and the numbers that matter.